FORT LAUDERDALE, Fla., Aug. 13 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. , a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that it has been selected by a leading European based Contract Research Organization (CRO) to provide eClinical solutions for a pivotal Phase III study in rheumatoid arthritis (RA). Phase III clinical studies serve to establish the safety and efficacy of investigational new drugs, in large patient populations, and are the last step prior to review for approval by the regulatory authorities, such as FDA and the EMEA . This particular RA study is expected to last 48 months and enroll close to 300 patients in 20 sites located in Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE OmniComm Systems, Inc.
CONTACT: Stephen Johnson, +1-954-377-1726, or Catherine Lemercier,
+1-954-473-1254 Extension 283, clemercier@omnicomm.com, of OmniComm
Systems, Inc; or Gary Nash, CEOcast, Inc., +1-212-732-4300,
gnash@ceocast.com
Web site: http://www.omnicomm.com/
